Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN‐6 trial
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a recent analysis including 16 million patients in a claims database, the incidence of GI complications increased among users of GLP-1 agonists.
“In a recent analysis including 16 million patients in a claims database, the incidence of GI complications increased among users of GLP-1 agonists.39”
From Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes (2025) · cites this paper as [39]
The Background and Results describe a post-hoc analysis of a randomized SUSTAIN-6 trial involving 3,297 patients, not an analysis of 16 million patients in a claims database. The reported outcomes are coronary events; the cited paper does not report increased gastrointestinal complications. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredBased on data from the SUSTAIN-6 and SELECT trials showing reduced cardiovascular disease in people with type 2 diabetes and in overweight/obese people without diabetes, it is likely that patients with type 1 diabetes would benefit from use of these novel agents not only for weight loss and improved glycemic control but also due to anticipated reductions in cardiovascular disease and diabetic keto
“In addition, based on data from the SUSTAIN-6 and SELECT trials showing reduced CVD in people with T2D and in OW/OB people without diabetes, 20,40 it is likely that patients with T1D would benefit from use of these novel agents not only for weight loss and improved glycemic control but also due to anticipated reductions in CVD and DKD.”
From Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes (2025) · cites this paper as [40]
The risk of pancreatitis was increased 9-fold, bowel obstruction 4-fold, and gastroparesis 3.67 times among GLP-1 users compared with bupropion-naltrexone users.
“The risk of pancreatitis was increased 9-fold, bowel obstruction 4-fold, and gastroparesis 3.67 times among GLP-1 users compared with bupropion-naltrexone users.39”
From Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes (2025) · cites this paper as [39]
The Methods and Results sections compare semaglutide with placebo and report coronary outcomes in patients with type 2 diabetes. Searches for pancreatitis, bowel obstruction, gastroparesis, bupropion-naltrexone, and the stated risk multiples found no passage addressing the claimed comparison. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 6× · see citing works
“Overall, 3297 patients were included in the present analyses: 1648 in the semaglutide group and 1649 in the placebo group (the same population as the original analyses).(3) The median follow-up was 2.”
BackgroundMethodInfluentialSelf-citationCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763 · see citing works
9. Pharmacologic Approaches to Glycemic Treatment: <i>Standards of Medical Care in Diabetes—2022</i>
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555 · see citing works
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660 · see citing works
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.037 · Cited by 466 · see citing works
Furberg, J. K., Rasmussen, S., Andersen, P. K., & Ravn, H. (2021) · Pharmaceutical Statistics · doi:10.1002/pst.2167 · Cited by 26 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Snell-Bergeon, J. K., Kaur, G., Renner, D., Akturk, H. K., Beatson, C., & Garg, S. K. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0328 · Cited by 40 · see citing works
- Authors
- Kolkailah, A. A., Lingvay, I., Dobrecky‐Mery, I., Aharonovich, A., David, J., Holse, C., Rasmussen, S., & McGuire, D. K.
- Affiliations
- Parkland Health & Hospital System (US)
- The University of Texas Southwestern Medical Center (US)
- Bnai Zion Medical Center (IL)
- Novo Nordisk (Denmark) (DK)
- Corresponding author
- Kolkailah, Ahmed A.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2022-12-23
- Volume
- 25
- Issue
- 4
- Pages
- 1117-1120
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- PMC
- PMC9991975
- OpenAlex
- W4311330119
- Cited by
- 6
- References
- 6
- Citations by year
- 2026: 3 · 2025: 2 · 2023: 1
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Obesity and Metabolism (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (T32HL125247)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, subcutaneous administration, type 2 diabetes, coronary artery disease, cardiovascular outcomes, SUSTAIN 6 trial, GLP-1 receptor agonists, high cardiovascular risk
- MeSH terms
- Semaglutide, Cardiovascular Diseases, Coronary Artery Disease, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
